Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIC-Peds: Nirmatrelvir/ritonavir in pediatric outpatients with COVID-19 at risk for severe disease
jRCT2031250096Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Apr 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19), sponsored by Pfizer. Primary endpoints: Maximum observed plasma concentration (Cmax) of nirmatrelvir and ritonavir, Area under the curve to the end of the dosing period (AUC0-tau) of nirmatrelvir and ritonavir and 4 more. Started Apr 2025; status: recruiting.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031250096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250096.